Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andrew Wei

Showing results (71-80 of 99) with videos related to

Pageof 10
Sort By:
Haematologica|July 2, 2015
Efficacy of an Fc-modified anti-CD123 antibody (CSL362) combined with chemotherapy in xenograft models of acute myelogenous leukemia in immunodeficient miceErwin M Lee, Dean Yee, Samantha J Busfield, et al.
BMC Cancer|November 15, 2022
Venetoclax combined with low dose cytarabine compared to standard of care intensive chemotherapy for the treatment of favourable risk adult acute myeloid leukaemia (VICTOR): Study protocol for an international, open-label, multicentre, molecularly-guided randomised, phase II trialRichard Dillon, Shanna Maycock, Aimee Jackson, et al.
Future Oncology (London, England)|January 20, 2016
Design of the randomized, Phase III, QUAZAR AML Maintenance trial of CC-486 (oral azacitidine) maintenance therapy in acute myeloid leukemiaGail J Roboz, Pau Montesinos, Dominik Selleslag, et al.
Genes & Development|January 27, 2012
Anti-apoptotic Mcl-1 is essential for the development and sustained growth of acute myeloid leukemiaStefan P Glaser, Erinna F Lee, Evelyn Trounson, et al.
Journal of Hematology & Oncology|November 14, 2025
Olutasidenib for mutated IDH1 acute myeloid leukemia: final five-year results from the phase 2 pivotal cohortJorge Cortes, Antonio Curti, Pierre Fenaux, et al.
Pathology|December 4, 2020
Laboratory quality assessment of candidate gene panel testing for acute myeloid leukaemia: a joint ALLG / RCPAQAP initiativeGreg Corboy, Jad Othman, Linda Lee, et al.
Blood Cancer Journal|March 2, 2019
Correction: High expression of HMGA2 independently predicts poor clinical outcomes in acute myeloid leukemiaMiriam Marquis, Cyrielle Beaubois, Vincent-Philippe Lavallée, et al.
Blood Cancer Journal|August 1, 2018
High expression of HMGA2 independently predicts poor clinical outcomes in acute myeloid leukemiaMiriam Marquis, Cyrielle Beaubois, Vincent-Philippe Lavallée, et al.
Implementation Science : IS|July 3, 2024
Re-Purposing the Ordering of Routine Laboratory Tests in Hospitalized Medical Patients (RePORT): protocol for a multicenter stepped-wedge cluster randomised trial to evaluate the impact of a multicomponent intervention bundle to reduce laboratory test over-utilizationAnshula Ambasta, Jayna M Holroyd-Leduc, Surakshya Pokharel, et al.
Cancer Discovery|January 13, 2021
Serine Biosynthesis Is a Metabolic Vulnerability in FLT3-ITD-Driven Acute Myeloid LeukemiaStefan Bjelosevic, Emily Gruber, Andrea Newbold, et al.
Pageof 10

Showing results (71-80 of 99) with videos related to

Sort By:
Pageof 10
Haematologica|July 2, 2015
Efficacy of an Fc-modified anti-CD123 antibody (CSL362) combined with chemotherapy in xenograft models of acute myelogenous leukemia in immunodeficient miceErwin M Lee, Dean Yee, Samantha J Busfield, et al.
BMC Cancer|November 15, 2022
Venetoclax combined with low dose cytarabine compared to standard of care intensive chemotherapy for the treatment of favourable risk adult acute myeloid leukaemia (VICTOR): Study protocol for an international, open-label, multicentre, molecularly-guided randomised, phase II trialRichard Dillon, Shanna Maycock, Aimee Jackson, et al.
Future Oncology (London, England)|January 20, 2016
Design of the randomized, Phase III, QUAZAR AML Maintenance trial of CC-486 (oral azacitidine) maintenance therapy in acute myeloid leukemiaGail J Roboz, Pau Montesinos, Dominik Selleslag, et al.
Genes & Development|January 27, 2012
Anti-apoptotic Mcl-1 is essential for the development and sustained growth of acute myeloid leukemiaStefan P Glaser, Erinna F Lee, Evelyn Trounson, et al.
Journal of Hematology & Oncology|November 14, 2025
Olutasidenib for mutated IDH1 acute myeloid leukemia: final five-year results from the phase 2 pivotal cohortJorge Cortes, Antonio Curti, Pierre Fenaux, et al.
Pathology|December 4, 2020
Laboratory quality assessment of candidate gene panel testing for acute myeloid leukaemia: a joint ALLG / RCPAQAP initiativeGreg Corboy, Jad Othman, Linda Lee, et al.
Blood Cancer Journal|March 2, 2019
Correction: High expression of HMGA2 independently predicts poor clinical outcomes in acute myeloid leukemiaMiriam Marquis, Cyrielle Beaubois, Vincent-Philippe Lavallée, et al.
Blood Cancer Journal|August 1, 2018
High expression of HMGA2 independently predicts poor clinical outcomes in acute myeloid leukemiaMiriam Marquis, Cyrielle Beaubois, Vincent-Philippe Lavallée, et al.
Implementation Science : IS|July 3, 2024
Re-Purposing the Ordering of Routine Laboratory Tests in Hospitalized Medical Patients (RePORT): protocol for a multicenter stepped-wedge cluster randomised trial to evaluate the impact of a multicomponent intervention bundle to reduce laboratory test over-utilizationAnshula Ambasta, Jayna M Holroyd-Leduc, Surakshya Pokharel, et al.
Cancer Discovery|January 13, 2021
Serine Biosynthesis Is a Metabolic Vulnerability in FLT3-ITD-Driven Acute Myeloid LeukemiaStefan Bjelosevic, Emily Gruber, Andrea Newbold, et al.
Pageof 10